Peptides
SLU-PP-332
SLU-PP-332 is a synthetic ERR agonist studied as an exercise-mimetic compound in metabolic research. Below, we compare vendors currently stocking research-grade SLU-PP-332 — not just a single sales page.
SLU-PP-332 is a synthetic ERR agonist studied as an exercise-mimetic compound in metabolic research. Below, we compare vendors currently stocking research-grade SLU-PP-332 — not just a single sales page.
Prices and testing claims are pulled from each vendor's product listing. Always confirm current price and COA (Certificate of Analysis) on the vendor's site before buying.
| Vendor | Price | Purity Testing | Code | |
|---|---|---|---|---|
 MuscleChemBest Value |
£49.99 | In-house testing | Buy Here → | |
 Amino Vault |
$64.60 | Third-party COA | Buy Here → | |
 Chemyo |
$79.99 (200mcg/ml solution) | Third-party COA | Buy Here → | |
 UK Sarms |
£69.99 – £89.99 | Third-party COA | Auto-applied | Buy Here → |
SLU-PP-332 is a synthetic small molecule developed by researchers at Saint Louis University as a selective agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ). It is a comparatively new research compound, first described in the scientific literature in 2023.
Research-grade SLU-PP-332 is typically supplied as a lyophilized powder in sealed vials or capsules, commonly at 5mg to 10mg strengths, intended for laboratory research use only.
SLU-PP-332 activates estrogen-related receptors, transcription factors that regulate genes involved in mitochondrial biogenesis and oxidative metabolism, independent of estrogen receptor signaling itself — a mechanism researchers have compared to the metabolic effects of endurance exercise.
The original 2023 study describing SLU-PP-332 found that treated mice showed increased running endurance and mitochondrial gene expression without additional exercise, which is why it is frequently described in the research community as an exercise-mimetic candidate.
Beyond endurance, SLU-PP-332 is studied for its effects on fat oxidation and metabolic rate in animal models, an area of interest given ERR's established role in regulating mitochondrial and metabolic gene networks.
SLU-PP-332 is an early-stage research compound with a very limited published safety record, restricted almost entirely to the original mouse studies. It has not been evaluated in humans, is not FDA-approved, and comprehensive toxicology and long-term safety data does not exist.
Doses used in the foundational mouse studies are documented in that specific research and do not translate to an established human dose. No human dosage of any kind has been clinically evaluated for SLU-PP-332.
Compound X does not sell SLU-PP-332 directly. We provide independent research, comparisons and vendor links — see the vendor comparison table above for current US, UK, Canada and Australia options.
SLU-PP-332 research is indexed on PubMed under search terms such as "SLU-PP-332 ERR agonist" and "estrogen related receptor exercise mimetic."
New guides, vendor comparisons and compound breakdowns every week.